HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress

Brandt A. Nichols, Nathaniel W. Oswald, Elizabeth A. McMillan, Kathleen McGlynn, Jingsheng Yan, Min S. Kim, Janapriya Saha, Prema L. Mallipeddi, Sydnie A. LaDuke, Pamela A. Villalobos, Jaime Rodriguez-Canales, Ignacio I. Wistuba, Bruce A Posner, Anthony J Davis, John D Minna, John B MacMillan, Angelique W Whitehurst

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cancer testis antigens (CTA) are expressed in testis and placenta and anomalously activated in a variety of tumors. The mechanistic contribution of CTAs to neoplastic phenotypes remains largely unknown. Using a chemigenomics approach, we find that the CTA HORMAD1 correlates with resistance to the mitochondrial complex I inhibitor piericidin A in non–small cell lung cancer (NSCLC). Resistance was due to a reductive intracellular environment that attenuated the accumulation of free radicals. In human lung adenocarcinoma (LUAD) tumors, patients expressing high HORMAD1 exhibited elevated mutational burden and reduced survival. HORMAD1 tumors were enriched for genes essential for homologous recombination (HR), and HORMAD1 promoted RAD51-filament formation, but not DNA resection, during HR. Accordingly, HORMAD1 loss enhanced sensitivity to g-irradiation and PARP inhibition, and HORMAD1 depletion significantly reduced tumor growth in vivo. These results suggest that HORMAD1 expression specifies a novel subtype of LUAD, which has adapted to mitigate DNA damage. In this setting, HORMAD1 could represent a direct target for intervention to enhance sensitivity to DNA-damaging agents or as an immunotherapeutic target in patients. Significance: This study uses a chemigenomics approach to demonstrate that anomalous expression of the CTA HORMAD1 specifies resistance to oxidative stress and promotes HR to support tumor cell survival in NSCLC.

Original languageEnglish (US)
Pages (from-to)6196-6208
Number of pages13
JournalCancer Research
Volume78
Issue number21
DOIs
StatePublished - Nov 1 2018

Fingerprint

DNA Damage
Oxidative Stress
Homologous Recombination
Testicular Neoplasms
Neoplasms
Antigens
Non-Small Cell Lung Carcinoma
DNA
Essential Genes
Placenta
Free Radicals
Testis
Cell Survival
Adenocarcinoma of lung
Phenotype
Survival
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress. / Nichols, Brandt A.; Oswald, Nathaniel W.; McMillan, Elizabeth A.; McGlynn, Kathleen; Yan, Jingsheng; Kim, Min S.; Saha, Janapriya; Mallipeddi, Prema L.; LaDuke, Sydnie A.; Villalobos, Pamela A.; Rodriguez-Canales, Jaime; Wistuba, Ignacio I.; Posner, Bruce A; Davis, Anthony J; Minna, John D; MacMillan, John B; Whitehurst, Angelique W.

In: Cancer Research, Vol. 78, No. 21, 01.11.2018, p. 6196-6208.

Research output: Contribution to journalArticle

Nichols, BA, Oswald, NW, McMillan, EA, McGlynn, K, Yan, J, Kim, MS, Saha, J, Mallipeddi, PL, LaDuke, SA, Villalobos, PA, Rodriguez-Canales, J, Wistuba, II, Posner, BA, Davis, AJ, Minna, JD, MacMillan, JB & Whitehurst, AW 2018, 'HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress', Cancer Research, vol. 78, no. 21, pp. 6196-6208. https://doi.org/10.1158/0008-5472.CAN-18-1377
Nichols, Brandt A. ; Oswald, Nathaniel W. ; McMillan, Elizabeth A. ; McGlynn, Kathleen ; Yan, Jingsheng ; Kim, Min S. ; Saha, Janapriya ; Mallipeddi, Prema L. ; LaDuke, Sydnie A. ; Villalobos, Pamela A. ; Rodriguez-Canales, Jaime ; Wistuba, Ignacio I. ; Posner, Bruce A ; Davis, Anthony J ; Minna, John D ; MacMillan, John B ; Whitehurst, Angelique W. / HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress. In: Cancer Research. 2018 ; Vol. 78, No. 21. pp. 6196-6208.
@article{ab63543a513f4242a2ac541c8299d5b3,
title = "HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress",
abstract = "Cancer testis antigens (CTA) are expressed in testis and placenta and anomalously activated in a variety of tumors. The mechanistic contribution of CTAs to neoplastic phenotypes remains largely unknown. Using a chemigenomics approach, we find that the CTA HORMAD1 correlates with resistance to the mitochondrial complex I inhibitor piericidin A in non–small cell lung cancer (NSCLC). Resistance was due to a reductive intracellular environment that attenuated the accumulation of free radicals. In human lung adenocarcinoma (LUAD) tumors, patients expressing high HORMAD1 exhibited elevated mutational burden and reduced survival. HORMAD1 tumors were enriched for genes essential for homologous recombination (HR), and HORMAD1 promoted RAD51-filament formation, but not DNA resection, during HR. Accordingly, HORMAD1 loss enhanced sensitivity to g-irradiation and PARP inhibition, and HORMAD1 depletion significantly reduced tumor growth in vivo. These results suggest that HORMAD1 expression specifies a novel subtype of LUAD, which has adapted to mitigate DNA damage. In this setting, HORMAD1 could represent a direct target for intervention to enhance sensitivity to DNA-damaging agents or as an immunotherapeutic target in patients. Significance: This study uses a chemigenomics approach to demonstrate that anomalous expression of the CTA HORMAD1 specifies resistance to oxidative stress and promotes HR to support tumor cell survival in NSCLC.",
author = "Nichols, {Brandt A.} and Oswald, {Nathaniel W.} and McMillan, {Elizabeth A.} and Kathleen McGlynn and Jingsheng Yan and Kim, {Min S.} and Janapriya Saha and Mallipeddi, {Prema L.} and LaDuke, {Sydnie A.} and Villalobos, {Pamela A.} and Jaime Rodriguez-Canales and Wistuba, {Ignacio I.} and Posner, {Bruce A} and Davis, {Anthony J} and Minna, {John D} and MacMillan, {John B} and Whitehurst, {Angelique W}",
year = "2018",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-18-1377",
language = "English (US)",
volume = "78",
pages = "6196--6208",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress

AU - Nichols, Brandt A.

AU - Oswald, Nathaniel W.

AU - McMillan, Elizabeth A.

AU - McGlynn, Kathleen

AU - Yan, Jingsheng

AU - Kim, Min S.

AU - Saha, Janapriya

AU - Mallipeddi, Prema L.

AU - LaDuke, Sydnie A.

AU - Villalobos, Pamela A.

AU - Rodriguez-Canales, Jaime

AU - Wistuba, Ignacio I.

AU - Posner, Bruce A

AU - Davis, Anthony J

AU - Minna, John D

AU - MacMillan, John B

AU - Whitehurst, Angelique W

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Cancer testis antigens (CTA) are expressed in testis and placenta and anomalously activated in a variety of tumors. The mechanistic contribution of CTAs to neoplastic phenotypes remains largely unknown. Using a chemigenomics approach, we find that the CTA HORMAD1 correlates with resistance to the mitochondrial complex I inhibitor piericidin A in non–small cell lung cancer (NSCLC). Resistance was due to a reductive intracellular environment that attenuated the accumulation of free radicals. In human lung adenocarcinoma (LUAD) tumors, patients expressing high HORMAD1 exhibited elevated mutational burden and reduced survival. HORMAD1 tumors were enriched for genes essential for homologous recombination (HR), and HORMAD1 promoted RAD51-filament formation, but not DNA resection, during HR. Accordingly, HORMAD1 loss enhanced sensitivity to g-irradiation and PARP inhibition, and HORMAD1 depletion significantly reduced tumor growth in vivo. These results suggest that HORMAD1 expression specifies a novel subtype of LUAD, which has adapted to mitigate DNA damage. In this setting, HORMAD1 could represent a direct target for intervention to enhance sensitivity to DNA-damaging agents or as an immunotherapeutic target in patients. Significance: This study uses a chemigenomics approach to demonstrate that anomalous expression of the CTA HORMAD1 specifies resistance to oxidative stress and promotes HR to support tumor cell survival in NSCLC.

AB - Cancer testis antigens (CTA) are expressed in testis and placenta and anomalously activated in a variety of tumors. The mechanistic contribution of CTAs to neoplastic phenotypes remains largely unknown. Using a chemigenomics approach, we find that the CTA HORMAD1 correlates with resistance to the mitochondrial complex I inhibitor piericidin A in non–small cell lung cancer (NSCLC). Resistance was due to a reductive intracellular environment that attenuated the accumulation of free radicals. In human lung adenocarcinoma (LUAD) tumors, patients expressing high HORMAD1 exhibited elevated mutational burden and reduced survival. HORMAD1 tumors were enriched for genes essential for homologous recombination (HR), and HORMAD1 promoted RAD51-filament formation, but not DNA resection, during HR. Accordingly, HORMAD1 loss enhanced sensitivity to g-irradiation and PARP inhibition, and HORMAD1 depletion significantly reduced tumor growth in vivo. These results suggest that HORMAD1 expression specifies a novel subtype of LUAD, which has adapted to mitigate DNA damage. In this setting, HORMAD1 could represent a direct target for intervention to enhance sensitivity to DNA-damaging agents or as an immunotherapeutic target in patients. Significance: This study uses a chemigenomics approach to demonstrate that anomalous expression of the CTA HORMAD1 specifies resistance to oxidative stress and promotes HR to support tumor cell survival in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85053735452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053735452&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-1377

DO - 10.1158/0008-5472.CAN-18-1377

M3 - Article

VL - 78

SP - 6196

EP - 6208

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -